These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 4629764)

  • 21. Serum lipids in an ambulary diabetic clientele. Effect of therapy with Atromidin (clofibrate).
    Bergqvist N
    Acta Med Scand; 1970 Mar; 187(3):213-8. PubMed ID: 5444978
    [No Abstract]   [Full Text] [Related]  

  • 22. [Hyperlipiemia and its therapy by clofibrate].
    Nakano M; Nakamura Y
    Iryo; 1969 Dec; 23(12):1473-8. PubMed ID: 5381198
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of long-term administration of clofibrate on the composition of blood lipids in patients with atherosclerosis.
    Poleszak J; Korolko A
    Pol Med J; 1972; 11(2):250-6. PubMed ID: 5071512
    [No Abstract]   [Full Text] [Related]  

  • 24. [Changes in the spectrum of serum lipids following 3 months administration of clofibrate Spofa].
    Cagánova A; Cagan S
    Cesk Farm; 1971 Nov; 20(9):341-6. PubMed ID: 5136172
    [No Abstract]   [Full Text] [Related]  

  • 25. [Long-term management of various hyperlipidemias using clofibrate].
    Studlar M; Pichler O; Kindler K
    Wien Med Wochenschr; 1975 Dec; 125(50-52):746-51. PubMed ID: 1229130
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.
    Hong XZ; Li LD; Wu LM
    Clin Exp Pharmacol Physiol; 2007; 34(1-2):27-35. PubMed ID: 17201732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Flaxseed oil attenuates nonalcoholic fatty liver of hyperlipidemic hamsters.
    Yang SF; Tseng JK; Chang YY; Chen YC
    J Agric Food Chem; 2009 Jun; 57(11):5078-83. PubMed ID: 19453104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological evaluation of membrane-moderated transdermal system of glipizide.
    Mutalik S; Udupa N
    Clin Exp Pharmacol Physiol; 2006; 33(1-2):17-26. PubMed ID: 16445694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of ursodeoxycholic acid on bile supersaturated with cholesterol in patients pretreated with clofibrate.
    Kutz K; Schulte A
    Z Gastroenterol; 1981 May; 19(5):231-6. PubMed ID: 7257479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Possibilities of the treatment of chronic liver diseases with and without vitamin B 12 -folic acid administration].
    Börner E
    Med Welt; 1972 Aug; 23(31):1077-80. PubMed ID: 4647306
    [No Abstract]   [Full Text] [Related]  

  • 31. Fatty liver and transaminase changes with adjuvant tamoxifen therapy.
    Liu CL; Huang JK; Cheng SP; Chang YC; Lee JJ; Liu TP
    Anticancer Drugs; 2006 Jul; 17(6):709-13. PubMed ID: 16917217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hyperlipemic conditions: results of their treatment with clofibrate-methandrostenolone].
    Ciammaichella A; Torcia L
    Boll Soc Ital Cardiol; 1971; 16(12):841-51. PubMed ID: 5150179
    [No Abstract]   [Full Text] [Related]  

  • 33. [Evaluation of the antilipaemic potential of etofylline clofibrate, its metabolites and clofibrate in dietary-induced hyperlipidaemia in the rat (author's transl)].
    Sterner W; Chibanguza G; Metz G
    Arzneimittelforschung; 1980; 30(11b):2038-41. PubMed ID: 7194056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
    Yu XX; Murray SF; Pandey SK; Booten SL; Bao D; Song XZ; Kelly S; Chen S; McKay R; Monia BP; Bhanot S
    Hepatology; 2005 Aug; 42(2):362-71. PubMed ID: 16001399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Metabolism of the isolated perfused rat liver following in vitro irradiation. Lactate, glucose, potassium, sodium, chloride as well as GOT and GPT activity in perfusion plasma].
    Stähler F; Sinn I
    Strahlentherapie; 1970 Apr; 139(4):496-505. PubMed ID: 5510087
    [No Abstract]   [Full Text] [Related]  

  • 36. [Non-alcoholic fatty liver].
    Zwimpfer J
    Praxis (Bern 1994); 2000 Oct; 89(43):1757-8. PubMed ID: 11103621
    [No Abstract]   [Full Text] [Related]  

  • 37. Clofibrate-induced muscle damage in patients with chronic renal failure.
    Pierides AM; Alvarez-Ude F; Kerr DN
    Lancet; 1975 Dec; 2(7948):1279-82. PubMed ID: 54800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of nonalcoholic fatty liver disease with type 2 diabetes: clinical features and independent risk factors in diabetic fatty liver patients.
    Jin HB; Gu ZY; Yu CH; Li YM
    Hepatobiliary Pancreat Dis Int; 2005 Aug; 4(3):389-92. PubMed ID: 16109522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction of serum lipids in familial hyperlipidemias by a tetralin derivative.
    Oriente P; Motolese M; Cerqua R; Mancini M
    Int Z Klin Pharmakol Ther Toxikol; 1969 Oct; 2(4):348-53. PubMed ID: 4903988
    [No Abstract]   [Full Text] [Related]  

  • 40. [Effect of chenodesoxycholic acid on serum lipids and enzymes (transaminases) in patients with biliary lithiasis].
    Bataller Sifre R; Pascual Bataller E; Rosique Martínez A; Miralles Espi MC
    Rev Esp Enferm Apar Dig; 1982 Feb; 61(2):141-4. PubMed ID: 7089362
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.